These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2280082)

  • 1. [pTa bladder tumors. II--Is it possible to predict ulterior infiltration?].
    Bittard H
    J Urol (Paris); 1990; 96(6):299-301. PubMed ID: 2280082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].
    Werner W; Smesny S; Schubert J
    Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):519-27. PubMed ID: 10996943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Surveillance and prognosis of "Ta" superficial tumors of the bladder. Homogeneous series of 138 cases followed for 1 to 18 years].
    Lachand AT; Texier J; Texier P
    Prog Urol; 2001 Jun; 11(3):466-71. PubMed ID: 11512459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical study of recurrence and progression of grade 3 superficial bladder tumor].
    Ikegami S; Tsuji A; Suzuki S; Sumitomo M; Kimura F; Asano T; Nakajima F; Hayakawa M
    Hinyokika Kiyo; 1999 May; 45(5):325-9. PubMed ID: 10410314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S; Guney N; Canogullari Z; Ergenekon E
    Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Superficial grade G2 tumors of the bladder: recurrence, progression, prognosis].
    Sebe P; Lebret T; Molinie V; Herve JM; Yonneau L; Lugagne PM; Saporta F; Orsoni JL; Butreau M; Botto H
    Prog Urol; 2003 Sep; 13(4):608-12. PubMed ID: 14650291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of low grade papillary bladder tumors.
    Herr HW; Donat SM; Reuter VE
    J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC; Lin AT; Chen KK; Chang LS
    Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence pattern for superficial bladder cancer.
    Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M; Sato Y; Hanzawa T
    Int J Urol; 2006 Jun; 13(6):686-91. PubMed ID: 16834643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.